Biodelivery Sciences International Inc Jumped Higher After Venbio Select Advisor Llc Got Stake

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Corporate Logo

During Q3 2018 the big money sentiment increased to 2.65. That’s change of 1.61, from 2018Q2’s 1.04. 6 investors sold all, 11 reduced holdings as BioDelivery Sciences International, Inc. ratio improved. 22 increased stakes while 23 funds acquired stakes. Funds hold 31.84 million shares thus 28.16% more from 2018Q2’s 24.84 million shares.

Hikari Ltd owns 150,000 shs or 0.04% of their US capital. Grandeur Peak Glob Advsrs Ltd Liability Corporation has 197,300 shs for 0.06% of their capital. Point72 Asset Limited Partnership holds 0.02% or 1.50 million shs in its capital. Quantitative Systematic Strategies Limited stated it has 0.02% of its capital in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Cortina Asset Management Ltd Liability Corporation has 1.97 million shs. 511,992 are owned by Geode Cap Ltd Llc. D E Shaw & Com Inc reported 161,235 shs or 0% of all its holdings. Dimensional Fund Advsrs Ltd Partnership has invested 0% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Prelude Mgmt Ltd owns 8,000 shs for 0% of their capital. Next Financial Gru Inc, Texas-based fund reported 69,050 shs. Valley National Advisers Incorporated, Pennsylvania-based fund reported 22,715 shs. Janney Mngmt Limited Co holds 36,582 shs. Cubist Systematic Strategies Limited Liability Company holds 0% of its capital in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) for 11,742 shs. Schwab Charles Mngmt has invested 0% of its capital in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). 5.44M are held by Venbio Select Advisor Lc.

BioDelivery Sciences International, Inc. had 9 insider sales and 0 insider purchases since August 17, 2018. This’s net activity of $699,789. Another trade for 16,161 shs valued at $61,250 was made by De Paolantonio Ernest Robert on Tuesday, December 4. On Wednesday, September 12 ODONNELL FRANCIS E JR also sold $428,284 worth of BioDelivery Sciences International, Inc. (NASDAQ:BDSI).

Venbio Select Advisor Llc acquired Biodelivery Sciences International Inc stake

Sec.gov filling SC 13G reported by Venbio Select Advisor Llc with Biodelivery Sciences International Inc can be reviewed on 000090266419001005.The Health Care–company’s 9.98% or 8,614,588 shares owned by the filler was posted in Venbio Select Advisor Llc�s filling.

On December 31, 2018 it was submitted as new holding in Biodelivery Sciences International Inc for filler.The Venbio Select Advisor Llc�s view may bring Biodelivery Sciences International Inc positive attention.We assume the sec form is good signal for Biodelivery Sciences International Inc. The filler has $380.08 million in assets institutional investor.

Biodelivery Sciences International Inc Institutional Changes

46 investors own Biodelivery Sciences International Inc says the latest Sec.gov forms. In Q3 2017 the institutional ownership is low, which is Infinity of the outstanding shares. By 1358863 shares it is increased. Institutional investors owned 20343527. In total 6 funds opened new Biodelivery Sciences International Inc stakes, 19 increased stakes. There were 8 that closed positions and 7 reduced them.

As of Q3 2017 Julian Baker And Felix Baker Baker Bros Advisors Lp is owning 0.01% of its US portfolio or 210021 shares. The stake that Grandeur Peak Global Advisors Llc posted worth 0.51% of its portfolio 1142481 shares. Further, Hikari Power Ltd posted stake worth 0.23% of the manager�s US portfolio. 50000 shares has AZ Hikari Power Ltd which is 0.20% of their stock portfolio. The 4410866 shares are owned by NY Broadfin Capital Llc. Biodelivery Sciences International Inc is 1.92% of its portfolio.

Venbio Select Advisor Llc website.

Investors wait BioDelivery Sciences International, Inc. (NASDAQ:BDSI)’s quarterly earnings on March, 21., as reported by RTT. earnings per share of $-0.11 is 62.07 % up from 2018’s $-0.29 EPS. Analysts at Wall Street see BioDelivery Sciences International, Inc.’s 10.00 % negative EPS growth compared to $-0.10 earnings per share for last quarter.

BDSI reached $4.55 during the last trading session after $0.19 change.Currently BioDelivery Sciences International, Inc. is uptrending after 30.55% change in last February 14, 2018. BDSI has 567,506 shares volume. BDSI outperformed the S&P 500 by 30.55%.

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction.The company has $322.19 million market cap. The firm provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, which consists of a small, erodible polymer film for application to the buccal mucosa.Last it reported negative earnings. It offers ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA, a buprenorphine buccal film for the treatment of chronic pain.

For more BioDelivery Sciences International, Inc. (NASDAQ:BDSI) news published briefly go to: Globenewswire.com, Seekingalpha.com, Benzinga.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “BioDelivery Sciences Announces Agreement with Broadfin Capital on Comprehensive Plan to Strengthen Business – GlobeNewswire” published on May 17, 2018, “BioDelivery Sciences beats by $0.04, beats on revenue – Seeking Alpha” on November 08, 2018, “The Daily Biotech Pulse: Big Pharma Earnings, Kiniksa Offering, FDA Decision Day For Aquestive – Benzinga” with a publish date: January 29, 2019, “BioDelivery Sciences Announces Pricing of $50 Million Equity Financing – GlobeNewswire” and the last “BioDelivery Sciences to Report Third Quarter 2018 Financial Results on November 8, 2018 – GlobeNewswire” with publication date: October 23, 2018.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.